Cathie Wood Just Bet Big on This Biotech Stock

Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) focuses connected companies successful the genomics sector, particularly successful healthcare. Since the opening of July, Wood has, done this Ark Invest exchange-traded money (ETF), bought $15.3 cardinal worthy of Ionis Pharmaceuticals (NASDAQ: IONS), a biotech institution based successful Carlsbad, California.

The banal is down astir 37% from its 2026 precocious earlier this month, with overmuch of that diminution coming aft it and its spouse AstraZeneca announced a astonishment late-stage proceedings nonaccomplishment regarding eplontersen, a medicine utilized to dainty patients with transthyretin amyloidosis cardiomyopathy, oregon ATTR-CM, a uncommon bosom disease. All of Wood's caller Ionis purchases came aft that announcement, suggesting she is taking vantage of the stock's diminution to bargain much shares portion maintaining a semipermanent presumption that the institution is worthy investing in.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Let's spot what she whitethorn beryllium seeing.

Ionis already had a large marketplace enlargement successful June

In June 2026, the Food and Drug Administration (FDA) approved Ionis's cause Tryngolza (olezarsen) for attraction of terrible hypertriglyceridemia (sHTG), a information characterized by elevated humor triglyceride levels. Tryngolza's archetypal support successful 2024 was for familial chylomicronemia syndrome (FCS), a uncommon illness that causes precocious levels of triglycerides successful the blood. FCS affects lone astir 3,000 radical successful the U.S., but the caller sHTG support expands its people marketplace to much than 3 cardinal imaginable patients successful the U.S. alone.

In objective trials, Tryngolza reduced triglyceride levels by up to 72% and, crucially, reduced life-threatening acute pancreatitis events by 85% to 91%. It is the lone approved therapy for sHTG that has been shown to dramatically trim this circumstantial pancreatic risk, giving it a competitory advantage.

While its caller proceedings setback means that Ionis won't beryllium capable to stock profits, income royalties, oregon aboriginal milestone payments for eplontersen for that indication, the cause was approved successful 2023 to dainty polyneuropathy of hereditary transthyretin-mediated amyloidosis successful adults.

A displacement to higher-margin, wholly owned commercialization

Historically, Ionis functioned arsenic a probe and improvement (R&D) engine, processing drugs and licensing them disconnected to larger pharmaceutical companies, including Biogen and AstraZeneca, successful speech for royalty cuts.